Animal healthcare company. Spun out of Pfizer in 2013. From 2001 to 2018, spending on animal healthcare went from $6.2B to $15.5B. Young people all have pets. One of the great thing is that a lot of the costs are out of the pocket, not many insurances companies in the market. Not a lot of generics that compete with the drugs, and getting new drugs approved for animals is faster. Very little debt. Good growth perspective. (Analysts’ price target is $106.33)

Medical devices company. Great company. Will continue to grow with the aging population. 73% of the business in the U.S., 23% in Europe and the rest emerging markets. Can grow their business internationally. Very little debt. Great story, great growth and operating margins. (Analysts’ price target is $201.12)

Likes the story. One of the largest bank in the U.S. Cost structure is coming down. Payout ratio is only 19%, could see a greater dividend. Trading close to 1X book value. Could certainly trade at 1.5-2X book at some point in time in the cycle. (Analysts’ price target is $32.90)

Expectations of earnings have fallen so companies come deliver at those expectations or higher. Bond yields have fallen a lot, reflecting slower world growth, but the stock market has rebounded a lot of in effect saying that the market is fine. The curve rate is flat, and inflation will remain low. In this environment you can still do reasonably well. The risk to global markets is the difficulty in getting out of QE going forward. How can interest rates rise in a strong market? How can world banks create the buffer they need if the economy declines later?

REITs REITs are one of the best-performing sectors in Canada lately paying high dividends. Apartment and industrial ones have done very well. Some have done poorly, but they are specific, like Boardwalk which focuses on Calgary. It may be tougher for REITs to generate much beyond yields, though, because they have run up so much in recent memory. Also, there's less capacity of apartments coming on. Lower interest rates are a tailwind.

A great company that makes medical devices and does hip replacements. A surgeon that uses their equipment won't suddenly switch to another brand; the doctor will stay with Stryker. A problem is that sometimes the FDA approves medical devices too quickly--though that isn't a problem with Stryker. This is a good long-term hold.

Are the Rec Rooms really profitable? Their costs seems high, according to their reports. CGX is competing with streaming companies--not only Netflix, but Disney and others. But they have done a great job increasing their revenue in areas of food. Many people have big TV screens, too, which is another problem. CGX has been creative in bringing opera, live hockey and gaming to its cinemas.

They will be competing with other streamers. Also, they spend $15 billion a year, a lot. However, they proved they can raise prices without losing their audience. But it'll be tougher for them to remain profitable at these levels, given Disney+ coming.

Not expensive, with an incredible balance sheet and tons of free cash flow. The big issue is that their iPhone is slowing down, offering smaller improvements only. Their services business creates less revenue that their phones. So they need to produce product that people will like. It's unclear how they will drive that. Apple can still generate healthy returns and buy shares, but don't expect massive stock price increases like the past. If they can push loyal customers into new areas, like streaming, then there's good potential.

Trades at 16x earnings and has had a good run lately. They have a strong hold on the router market, but they haven't seen as much topline growth as their peers. Instead, they grow by acquisition. A great company that can buyback shares and increase its dividend. But you won't see the same growth as in the past.

(A Top Pick Apr 26/18, Up 6%) The Dollar Tree business does very well, but Family Dollar doesn't. There was good same-store sales growth at first, but things fell apart. This acqusition hasn't gone well and recently an activist investor has bought stock and is trying to change the company. Dollar Tree took on too much. He sold his shares.

(A Top Pick Apr 26/18, Down 2%) Still likes it. Trades at 10x earnings, a little above book value. Pays a 2.2% dividend. They can buyback their shares and increase their dividend at a 21% payout ratio that they can easily take to 40%. They rank 1, 2 or 3 in the industries they work in like investment banking and credit cards. They have a great opportunity to grow businesses as their book value grows rapidly. BAC can--and has--endure a period of flat yield curve.

(A Top Pick Apr 26/18, Up 31%) Also a top pick today, so details there. Good managers and type of business.

He sold it. It's cheap stock, but the issue is they can't integrate Aetna well. Also, they're considering a new store format from a vertical perspective to become more of a health centre. He doesn't think this vertical integration makes sense and expects more downside until CVS can show something positive from this integration. It doesn't help that American politicians are decrying rising healthcare costs.

Pays a steady 8% yield. Trades at price-to-AFFO at 8.2x. But they carry a lot of debt. Net debt to EBITDA is 4.6.x. This is moving sideways, so it's a good entry point.